LEGN Legend Biotech Earnings Miss: EPS Down 650%

Legend Biotech Corporation (LEGN) reported first-quarter earnings on May 12, 2026, delivering disappointing results that fell short of analyst expectations. The clinical-stage biopharmaceutical company reported earnings per share of negative $0.15, missing the estimate of negative $0.02 by a significant margin. Revenue came in at $305.1 million, just shy of the $306.5 million forecast. The earnings miss marks a concerning trend for the CAR-T cell therapy developer, which continues to burn cash while advancing its pipeline toward commercialization.

LEGN Earnings Results: Major EPS Miss

Legend Biotech’s first-quarter earnings revealed a substantial shortfall in profitability metrics. The company reported a loss per share of $0.15, representing a 650% miss against the consensus estimate of negative $0.02. This marks a significant deterioration from the prior quarter’s loss of $0.08 per share reported in March 2026.

EPS Performance Deterioration

The widening loss per share reflects mounting operating expenses as the company advances its clinical programs. The $0.15 loss per share is the worst quarterly result in the past four quarters, surpassing even the $0.11 loss reported in November 2025. This trend suggests accelerating cash burn as LEGN invests heavily in research and development activities.

Revenue Nearly Flat

Revenue declined marginally to $305.1 million from the $306.3 million reported in the prior quarter. The miss of just $1.4 million represents a 0.46% shortfall against expectations. While revenue remains relatively stable, the company’s inability to grow sales while losses expand raises concerns about operational efficiency and path to profitability.

Quarterly Comparison: Worsening Trend

Examining LEGN’s performance across the last four quarters reveals a deteriorating earnings trajectory despite relatively stable revenue. The company has consistently missed EPS estimates, with losses widening significantly in the most recent quarter.

Four-Quarter EPS Trend

In August 2025, LEGN reported a loss of $0.34 per share. By November, losses improved to $0.11. March 2026 showed further improvement to $0.08 per share. However, the latest quarter reversed this positive momentum with a loss of $0.15 per share. This reversal suggests operational challenges or increased spending on clinical development activities.

Revenue Stability Masks Profitability Crisis

Revenue has remained relatively consistent, ranging from $255.9 million to $306.3 million over four quarters. The $305.1 million reported this quarter falls within this range, indicating stable commercial performance. However, flat revenue combined with expanding losses demonstrates that LEGN’s cost structure remains unsustainable without significant revenue growth or expense reduction.

What the Results Mean for LEGN Stock

The earnings miss and widening losses present a mixed picture for investors. While the stock gained 1.45% on the day following the announcement, trading at $28.67, the underlying fundamentals remain concerning. The company’s market cap of $5.3 billion reflects investor optimism about future pipeline success rather than current financial performance.

Cash Burn and Runway Concerns

LEGN’s negative operating cash flow and free cash flow indicate the company is burning through cash reserves to fund operations. With a cash position of approximately $5.13 per share, or roughly $948 million in total cash, the company has runway to continue operations. However, accelerating losses could deplete reserves faster than anticipated, potentially requiring capital raises that dilute shareholders.

Analyst Sentiment Remains Positive

Despite the earnings miss, analyst consensus remains bullish with 13 buy ratings and only 2 hold ratings. Meyka AI rates LEGN with a grade of B, suggesting the market believes in the company’s long-term potential. The stock’s year-to-date gain of 31.9% reflects confidence in the CAR-T pipeline, particularly the lead candidate LCAR-B38M for multiple myeloma treatment.

Forward Outlook and Key Catalysts

Legend Biotech’s path forward depends on successful clinical development and eventual commercialization of its CAR-T therapies. The company faces critical milestones that could reshape investor sentiment and financial performance.

Pipeline Development Timeline

LEGN’s lead program, LCAR-B38M, represents the company’s primary value driver. The collaboration with Janssen Biotech for development and commercialization of ciltacabtagene autoleucel provides validation and potential revenue sharing. Success in Phase III trials for multiple myeloma could represent a major inflection point for the company’s financial trajectory.

Path to Profitability

The company must demonstrate revenue growth acceleration or achieve significant cost reductions to reach profitability. Current R&D spending represents 40% of revenue, indicating heavy investment in pipeline advancement. As clinical programs advance toward commercialization, revenue should increase substantially, but this remains years away. Investors should monitor quarterly cash burn rates and pipeline progress closely for signs of improvement.

Final Thoughts

Legend Biotech’s Q1 2026 earnings showed a significant EPS miss and widening losses despite stable revenue, raising profitability concerns. The $0.15 loss per share represents a 650% miss against estimates. While the company maintains $948 million in cash and a promising pipeline including LCAR-B38M, investors must monitor cash burn rates and clinical progress closely. Success depends on converting pipeline potential into commercial revenue within 2-3 years.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.